Tetracycline Antibiotics Impair Mitochondrial Function and Its Experimental Use Confounds Research

Iliana A. Chatzispyrou1, Ntsiki M. Held1, Laurent Mouchiroud2, Johan Auwerx2, and Riekelt H. Houtkooper1

Abstract

Tetracyclines, a class of antibiotics that target bacterial translation, are commonly used in research for inducible gene expression using Tet-ON/Tet-OFF systems. However, such tetracycline-inducible systems carry a risk. Given that mitochondria have a "bacterial" ancestry, these antibiotics also target mitochondrial translation and impair mitochondrial function. Indeed, treatment with doxycycline—a tetracycline derivative—disrupts mitochondrial proteostasis and metabolic activity, and induces widespread gene-expression changes. Together, this affects physiology in well-established model systems ranging from cultured cells to simple organisms and to mice and plants. These changes are observed with doxycycline doses that are widely used to regulate gene expression. In light of these findings, and bearing in mind the conserved role of mitochondria in metabolism and whole organism homeostasis, we caution against the use of tetracyclines in experimental approaches. The use of newly developed tetracycline-based systems that are more sensitive could be an alternative; however, even if no overt mitochondrial toxicity is detected, widespread changes in gene expression may sensitize cells to the intended tetracycline-controlled loss or gain of function, thereby introducing a "two-hit model." This is highly relevant for cancer research, as mitochondrial metabolism holds a central position in the reallocation of nutrients for biomass production known as the Warburg effect. Cancer Res; 75(21); 4446–9. ©2015 AACR.

Introduction

Mitochondria are at the core of cellular metabolism, as they participate in the final breakdown of nutrients and produce ATP after a series of oxidation reactions that take place in the mitochondrial subcompartments. Next to their vital metabolic role, they are also involved in many other important processes of the cell, such as calcium homeostasis, apoptosis, and intracellular signaling (1). Considering the versatile functions of mitochondria, it is no surprise that dysfunction of these organelles can lead to manifestation of different diseases affecting various tissues and with symptoms of ranging severity that can even be life-threatening (2). In recent years, mitochondrial dysfunction has also been implicated in multifactorial age-related diseases such as diabetes mellitus, Parkinson’s disease, and cancer. Consequently, there has been an ever-growing interest in mitochondria as targets for pharmacologic interventions (3).

Mitochondria as Bacteria in Our Cells

An important feature of mitochondria, which is reflected in both its unique ultrastructure and physiology, is its eubacterial ancestry. Mitochondria are derived from the endosymbiosis of an ß-proteobacterium with a host amitochondriate cell, an event that is considered to have given rise to the modern eukaryotic cell (4). Throughout evolution, most of the endosymbiont’s genome was transferred to the nucleus of the host cell, but mitochondria still harbor remnants of the ancestral bacterial genome and have retained their own transcriptional and translational machinery. Mitochondria contain several copies of this circular double-stranded molecule (mitochondrial DNA or mtDNA) that encodes for 13 core subunits of the oxidative phosphorylation (OXPHOS) complexes and for specific mitochondrial tRNAs and rRNAs (3). Because all other mitochondrial proteins—including the remainder of the OXPHOS subunits—are encoded by nuclear DNA (nDNA), the stoichiometric balance between both genomes is tightly regulated (5). Disruption of this balance, a state we previously termed mitonuclear protein imbalance, occurs when either the nuclear or the mitochondrial protein synthesis is perturbed. Such imbalance leads to the activation of the mitochondrial unfolded protein response (UPRmit), an adaptive stress-response pathway working to restore protein homeostasis within the mitochondrial matrix (6, 7). Moderate mitochondrial dysfunction and UPRmit activation is beneficial as it allows mitochondria to recuperate, whereas prolonged mitochondrial stress can ignite more terminal responses, including apoptosis. For example, RNAi-mediated knockdown of nDNA-encoded OXPHOS protein subunits led to UPRmit activation and lifespan extension in both fruit flies and the nematode C. elegans (8, 9). Similar effects were observed after inhibiting mtDNA replication and transcription...
with ethidium bromide treatment or after attenuation of mitochondrial translation by knockdown of components of the mito-ribosome in *C. elegans* (5, 10). On the other hand, pathogenic mutations in these pathways are linked to severe disorders that often present in infancy (2), emphasizing the delicate intergenomic balance.

Given the "bacterial" origin of mitochondria, it is not surprising that antibiotics targeting bacterial translation—such as tetracyclines and chloramphenicol—can also inhibit mitochondrial translation (11). Indeed, similar to RNAi-mediated downregulation of the mitochondrial translational machinery, treatment with doxycycline—an antibiotic belonging to the family of tetracyclines—induced mitonuclear protein imbalance, impaired mitochondrial respiration, activated UPRmt, and dose dependently extended the nematode lifespan (5). Similar effects on mitochondrial function and proteostasis were observed in tissues of mice fed with doxycycline, as well as in human and murine cell–based models, where doxycycline reduced mitochondrial respiration and induced UPRmt (5, 12).

On an organismal level, doxycycline proved beneficial on some physiologic aspects, as it increased motility in worms and flies, and extended the lifespan of worms (5, 12). At the same time, however, both doxycycline-treated models presented with developmental delay and physiologic impairment related to body size and fecundity (12). Even plants (*Arabidopsis thaliana*) treated with doxycycline displayed marked growth retardation, whereas on a molecular level they presented with mitochondrial dysfunction and activated UPRmt (12). These findings underscore the immense effects of doxycycline on mitochondrial function and whole-body physiology through a mechanism that is conserved from plants and invertebrates to mice and humans (Fig. 1).

**Mitochondria in Cancer**

Accumulating evidence suggests that functional mitochondria are essential for cancer cell survival and proliferation. The emerging role of mitochondrial bioenergetics, biogenesis, and signaling pathways on tumorigenesis has drawn the attention to the organelle’s function as a potentially fruitful field for cancer therapy development. Tumor cells have in essence an opposite metabolic profile from that of normal cells in differentiated tissues. In the mid-1920s, Otto Warburg observed that cancer cells produce large quantities of lactate even in the presence of ample oxygen, a state he termed "aerobic glycolysis" (13). We now know that increased...
glycolytic rates ensure faster supply of metabolic intermediates essential for fatty acid, amino acid, and nucleotide synthesis, facilitating rapid growth and division of tumor cells (14). At the same time, the mitochondrial tricarboxylic acid (TCA) cycle is highly active to provide precursors for biomass production and bioenergetics, a situation that can only be maintained through efficient replenishment of TCA cycle intermediates, for instance, through glutamine addiction, a phenomenon called anaplerosis (14). Thus, mitochondria in cancer cells remain metabolically active, meeting their bioenergetic needs by using alternative substrates while also supplying metabolic intermediates to sustain their proliferative capacity.

The relevance of mitochondrial metabolism in cancer is emphasized by the identification of tumors with mtDNA mutations (15); these mtDNA mutations seem to alter mitochondrial metabolism, enhance tumorigenesis, and allow cancer cell adaptation to changing environment. In addition, mutations in nDNA-encoded mitochondrial genes, including TCA cycle enzymes succinate dehydrogenase subunits (SDH), fumarate hydratase (FH), and isocitrate dehydrogenase 2 (IDH2), contribute to tumorigenesis as well as tumor progression (16). Another example of the vital role of mitochondria for tumor progression, is the finding that reduction of systemic copper has antiproliferative effects, by reducing activity of the mitochondrial enzyme cytochrome c oxidase, which leads to a decrease in ATP levels despite increased glycolysis rates (17). In addition to these metabolic switches, mitochondrial metabolism can also promote the production of mitochondrial reactive oxygen species (ROS) and change the cellular redox status. Mitochondrial ROS are important signaling molecules in the context of tumorigenesis by modifying the transcriptional activities of factors such as HIF-1, FOS, and JUN to change gene expression and stimulate cancer cell proliferation (15). These findings strongly support the fact that mitochondrial function is fundamental for cancer cells survival and proliferation, and in this light it is interesting that specific antibiotics—which target mitochondrial function—were identified as antiproliferative treatment (18). As such, the reemergence of mitochondria as a central metabolic hub required for tumorigenesis highlights its potential as a target for cancer therapy.

Tetracyclines in Cancer Research

The rise of the genomic era has allowed researchers to investigate the molecular function of many genes in great detail, but the drastic adverse effects of complete gain- or loss-of-function called for a more subtle approach. To serve this purpose, tetracyclines in cancer research—intrinsically, but given the central role of mitochondria in cellular physiology, this is also relevant for other fields, including cancer. So what is the alternative? New tetracycline-responsive systems have been developed that are more sensitive, and hence require lower doxycycline doses that do not cause overt adverse effects on mitochondrial function or global gene expression (24). Nevertheless, we propose that mild, even nonmeasurable, changes may sensitize a cell or organism to the intended alteration in gene expression, and thereby introduce a "two-hit model" (12). Other inducible systems, such as the tamoxifen-responsive estrogen receptor, also suffer from adverse effects, particularly in the liver of mice that have been engineered with this type of regulation expression under normal conditions, the TetR protein binds to the TetO sequence and thereby inhibits expression of the operon. The presence of tetracyclines, however, interrupts TetR binding to TetO and allows expression of the operon (19). TetR and TetO were the foundation of the commonly used Tet-ON/Tet-OFF system (21, 22). The Tet-OFF system was established by fusing TetR to a VP16 transcription activation domain that binds to multiple TetO sequences to drive transcription of a transgene with a minimal promoter (e.g., TATA box; ref. 21). In this case, the tetracycline-controlled transactivator (tTA) loses its binding potential to TetO upon tetracycline supplementation, and thereby prevents transgene expression. In the Tet-ON set-up or reversed transactivation (rTFA), the transgene transcription is only induced by rTFA binding to TetO upon addition of tetracycline or its more stable derivative doxycycline (22). Because gene expression can be regulated in a spatiotemporal manner, both the Tet-ON and Tet-OFF have been popular tools in cell culture models as well as model organisms, including mice (19).

Despite all the enthusiasm, the use of tetracyclines in such experimental setup comes at a cost. The inhibition of mitochondrial translation through tetracyclines, for instance, doxycycline, instigates adverse effects on mitochondria at the concentration generally used in Tet-ON/Tet-OFF systems (Fig. 1). Doxycycline exposure, even at low concentrations, increased glycolytic metabolism and markedly reduced the oxygen consumption of several human cell lines, including lung, prostate, and cervical cancer cell lines (23). We recently demonstrated that exposure to low-concentration doxycycline elicits similar adverse effects, that is, mitochondrial protein imbalance and decreased oxygen consumption (12). This mitochondrial dysfunction was found in several of the commonly used cell lines, such as HeLa, HEK293T, and Hepa 1–6. In addition, this metabolic stress was conserved in other model organisms, including worms, flies, mice, and even plants. Strikingly, a reanalysis of microarray transcriptome profiles of the human bladder cancer cell line RT112 exposed to doxycycline showed a 10% change in global gene expression (12), confirming the molecular basis for the widespread adverse effects of this treatment (Fig. 1).

Perspectives

The Tet-ON/Tet-OFF system has allowed a more intricate study of gene function without the dramatic adverse effects associated with gain- or loss-of-function mutants. Nevertheless, it has become apparent that gene-expression regulation using doxycycline or similar antibiotics also induces molecular changes that can seriously confound the experimental outcome. Therefore, we advocate against the use of doxycycline in such systems. This not only applies for researchers investigating mitochondrial function specifically, but given the central role of mitochondria in cellular physiology, this is also relevant for other fields, including cancer. So what is the alternative? New tetracycline-responsive systems have been developed that are more sensitive, and hence require lower doxycycline doses that do not cause overt adverse effects on mitochondrial function or global gene expression (24). Nevertheless, we propose that mild, even nonmeasurable, changes may sensitize a cell or organism to the intended alteration in gene expression, and thereby introduce a "two-hit model" (12). Other inducible systems, such as the tamoxifen-responsive estrogen receptor, also suffer from adverse effects, particularly in the liver of mice that have been engineered with this type of regulation expression.
The only setup that so far appears to be safe is the light-switchable system that is responsive to blue light (26), although further research is necessary to establish whether absorption of this light by specific proteins indeed does not interfere with cellular function.

Finally, the extensive use of tetracycline in the clinic and in livestock should be carefully evaluated and monitored. In the United States and countries in the European Union, the supply of tetracycline destined for animal use exceeds 8.5 million kilograms a year (27, 28). Similar to the exogenously added antibiotics, for example, in the Tet-ON/Tet-OFF, these antibiotics may end up in the serum used in cell culture media, and thereby confound experimental outcomes in research. More importantly, at least from a global health perspective, high concentrations of antibiotics are ending up in the environment. Little is known about the exact antibiotic concentrations in soils, but tetracycline concentrations up to 300 mg/kg have been reported in specific contexts, such as swine manure (29) or agricultural fields in Beijing suburbs (30). The magnitude of the effects on plants, animals, and humans requires more investigation, but it is clear that the excessive use of antibiotics can have a major impact on public health (Fig. 1). This involves the potential hazards of antibiotic resistance, disturbed gut microbiota, but also mitochondrial toxicity.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

Work in the Houtkooper group is financially supported by a grant from the Rembrandt Institute for Cardiovascular Science, an ERC Starting grant [no. 638230], and a VENI grant from ZonMW [no. 91613050]. Work in the I.A. laboratory is supported by the Ecole Polytechnique Federale de Lausanne, the NIH [RO1AG043930], the Swiss National Science Foundation [31003A-124713], and Systems X [51RTPO-151019]. L. Mouchiroud is supported by an FBM fellowship, and I.A. Chatzispyrou by an AMC PhD Scholarship.

Received June 15, 2015; revised July 3, 2015; accepted July 14, 2015; published OnlineFirst October 16, 2015.